Report Store Get Proposal

Home Blog Gastroenterology 2

Gastroenterology

NASH Emerging Therapies The Path Forward

Articles

NASH Emerging Therapies: The Path Forward

If you’ve been keeping up with our previous posts, you already have a solid understanding of nonalcoholic steatohepatitis (NASH) and its impact. We’ve previously examined the dominance of off-label therapies in the NASH therapeutics market and the challenges associated with this approach. In this post, we’ll take a deeper dive into the future of NASH treatments, exploring emerging therapies and innovations that could reshape the landscape in the years to come. In 2024, the world witnessed a significant milestone with the approval of REZDIFFRA (resmetirom), the first drug specifically designed to treat nonalcoholic steatohepatitis (NASH) in adults. NASH, a severe fo...

Explore More...

impact-of-surgical-cameras

The Evolution and Impact of Surgical Cameras in Modern Medicine

smart-pills-future-outlook

From Science Fiction to Reality: Investigating the Market Dynamics and Growing Demand for the Smart Pills

medtech-news-for-vygon-butterfly-network-cosm-medical

Vygon Launched Nutrisafe2 System; Butterfly Network Launched Third-Gen Ultrasound; Cosm Medical Won FDA Clearance; FDA Cleared Sequel Med Tech Automated Insulin Delivery System; IceCure Medical Reported Positive Topline Results; Cerus Announced Positive Results in Blood Purification Trial

digestive-health-products-key-factors-and-market-dynamics

Digestive Health Products: Exploring the Market Dynamics and Key Factors Driving the Demand

pharma-news-for-bms-orchard-madrigal-astrazeneca

Bristol Myers Squibb’ Karuna Therapeutics Buyout; Orchard Therapeutics’ Lenmeldy FDA Approval; Madrigal Pharmaceuticals’ Rezdiffra FDA Approval; AstraZeneca’s Acquisition of Amolyt Pharma; Prilenia’s Pridopidine EU Marketing Approval

MedTech News for X-trodes, Lumicell, Konesksa

Johnson & Johnson’s Tecnis PureSee lens; Sparrow BioAcoustics’s Stethoscope Software; Better Therapeutics’s MASH Treatment; X-trodes’ Wearable “Skin” Solution; Lumicell’s LUMISIGHTTM; Konesksa Enrolled First Patient in Learns Observational Study

Pharma News for GSK, Gilead, CSL, CymaBay

GSK Receives FDA Fast Track Designation for Bepirovirsen; Gilead to Acquire CymaBay Therapeutics; CSL Announces Top-line Results from the Phase III AEGIS-II Trial; Ruxoprubart Scores FDA Orphan Drug Designation for PNH Treatment; CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar; Biogen Received European Commission Approval for SKYCLARYS

dupixent-for-eosinophilic-esophagitis-treatment

Dupixent Breaks Ground: First and Only Eosinophilic Esophagitis Treatment for Pediatric Patients

Pharma News for Merck, BMS, Sanofi, Juvena

Merck’s KEYTRUDA as Adjuvant Therapy for RCC Patients; BMS Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma for Multiple Myeloma; FDA Approves Dupixent for Eosinophilic Esophagitis; Juvena Receives FDA Orphan Drug Designation for JUV-161; European Commission Authorizes GSK’s Omjjara; ENHERTU Granted Priority Review in the US for for metastatic HER2-positive Solid Tumors

MedTech News for AngioDynamics, Enhatch, AbSolutions

FDA Breakthrough Device Designation to Pi-Cardia’s ShortCut; AbSolutions Med’s REBUILD Bioabsorbable Abdominal Wall Closure Device; AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter; Enhatch Announces FDA Clearance for a TKA Patient-Specific Instrumentation System

MedTech News for Epredia, Olympus, Neuralace, Bloomlife

Epredia Announced the US Launch of SlideMate Laser; Olympus, Canon Medical Announced Partnership; FDA Cleared Painful Diabetic Neuropathy Neurostim Therapy from Neuralace; FDA Clearance to Bloomlife’s Bloomlife MFM-Pro; BrainsWay Initiated New Studies of Non-Invasive Neurostim; Gore Enrolled First Patients in Expandable Stent Graft Trial

A Glance at Key Insights From 42nd J.P. Morgan Annual Healthcare Conclave

MedTech News for Enovis, AnX Robotica, CGBio

HR Pharmaceuticals Announced Collaboration with Poiesis Medical; Enovis Acquired Lima Corporate; AnX Robotica Announced FDA Clearance for ProScan; FDA Breakthrough Device Designation for CGBio’s ‘NOVOSIS PUTTY’; EndoSound Received 510(k) Clearance for Breakthrough EVS Innovation; Boston Scientific Initiated AVANT GUARD Clinical Trial

Pharma News for Merck, Ipsen, bluebird bio

Merck and Moderna Initiate Study to Evaluate V940; FDA Approves Vertex and CRISPR Therapeutics’ CASGEVY for SCD; Novartis Updated on its Investigational Iptacopan Phase III Study; FDA Grants Priority Review for New Drug Application for Elafibranor; FDA Approves bluebird bio’s LYFGENIA for Patients SCD; FDA Fast Track Designation for DMD Gene Therapy

Pharma News for Sanofi, Sosei, AstraZeneca, Arcturus

Dupixent Significantly Reduced COPD Exacerbations; Sosei Heptares to Regain Ownership of GSK4381406; AstraZeneca Gains Rights to Usynova’s KRAS Inhibitor; FDA Approvs OGSIVEO for Desmoid Tumors; Orphan Drug Designation for ARCT-032 for the Cystic Fibrosis; FDA Fast Track Designation for ADP101 for Food Allergies

Pharma News for AskBio, Almirall, Bayer, Pfizer

Key Updates on Phase 1 Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type; European Commission Approves EBGLYSS; Bayer Stopped OCEANIC-AF Study; Pfizer and Astellas’ XTANDI Approved by FDA; FDA Orphan Drug Designation to Epic Bio’s EPI-321; FDA Fast Track Designation to Chemomab’s CM-101 for PSC

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly